Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study

CureGN Consortium

doi:10.1016/j.ekir.2020.06.041

Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study

CureGN Consortium

Medicine - Renal and Hypertension Division

Research output: Contribution to journal › Article › peer-review

18 Scopus citations

Abstract

Introduction: Prior cross-sectional studies suggest that health-related quality of life (HRQOL) worsens with more severe glomerular disease. This longitudinal analysis was conducted to assess changes in HRQOL with changing disease status. Methods: Cure Glomerulonephropathy (CureGN) is a cohort of patients with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, IgA vasculitis, or IgA nephropathy. HRQOL was assessed at enrollment and follow-up visits 1 to 3 times annually for up to 5 years with the Patient-Reported Outcomes Measurement Information System (PROMIS). Global health, anxiety, and fatigue domains were measured in all; mobility was measured in children; and sleep-related impairment was measured in adults. Linear mixed effects models were used to evaluate HRQOL responsiveness to changes in disease status. Results: A total of 469 children and 1146 adults with PROMIS scores were included in the analysis. HRQOL improved over time in nearly all domains, though group-level changes were modest. Edema was most consistently associated with worse HRQOL across domains among children and adults. A greater number of symptoms also predicted worse HRQOL in all domains. Sex, age, obesity, and serum albumin were associated with some HRQOL domains. The estimated glomerular filtration rate (eGFR) was only associated with fatigue and adult physical health; proteinuria was not associated with any HRQOL domain in adjusted models. Conclusion: HRQOL measures were responsive to changes in disease activity, as indicated by edema. HRQOL over time was not predicted by laboratory-based markers of disease. Patient-reported edema and number of symptoms were the strongest predictors of HRQOL, highlighting the importance of the patient experience in glomerular disease. HRQOL outcomes inform understanding of the patient experience for children and adults with glomerular diseases.

Original language	English (US)
Pages (from-to)	1679-1689
Number of pages	11
Journal	Kidney International Reports
Volume	5
Issue number	10
DOIs	https://doi.org/10.1016/j.ekir.2020.06.041
State	Published - Oct 2020

Bibliographical note

Funding Information:
Funding for the CureGN consortium is provided by UM1DK100845, UM1DK100846, UM1DK100876, UM1DK100866, and UM1DK100867 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Patient recruitment is supported by NephCure Kidney International. This project was also supported in part by UL1TR002240 from the National Center for Advancing Translational Sciences (NCATS) for the Michigan Institute for Clinical and Health Research.

Funding Information:
JT owns equity/stock in General Electric and Procter & Gamble, and receives grant support from Pfizer Inc. TS receives consulting fees and advisory board membership fees from ALNYLAM and current grant support and research funding from National Institutes of Health–National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK), Bristol-Myers-Squibb, Retrophin, Mallinckdrodt, and Alexion; and royalty from UpToDate. HF reports current grant support RANSFORM KL2 Scholars Mentored Career Development “Genomic Disorders, Chronic Kidney Disease and Neurocognitive Status in Children.” AF receives consulting fees and advisory board membership fees from Variant Pharmaceutical, DImerix ONO; Equity/stock Variant Pharmaceutical (unrelated), NIH grant support. PHN reports current grant support from NIH Immune Tolerance Network. CBS receives consulting fees and advisory board membership fees from Kite Medical. CW reports lecture fees from Mallinckrodt Pharmaceuticals. SB reports current grant support for multicenter NIH-sponsored trials. DSG receives consulting fees and advisory board membership fees paid to the University of Michigan; current grant support from Retrophin, Complexa, BMS, Variant, Goldfinch, NIH; and additional support from Nephcure Kidney International is under negotiation. KRT receives consulting fees and advisory board membership fees from Eli Lilly and Company, Boehringer Ingelheim, Astra Zeneca, Gilead, Goldfinch Bio; lecture fees from Eli Lilly and Company, Astra Zeneca; travel support from Eli Lilly and Company; current grant support from NIDDK, NCATS, and CDC; and additional support from Goldfinch Bio is under negotiation. All the other authors declared no competing interests.

Publisher Copyright:
© 2020

Keywords

edema
health-related quality of life
patient-reported outcomes
primary glomerular disease

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/j.ekir.2020.06.041

Find It

Find It at U of M Libraries

Cite this

@article{e5e6ac387f1249298549a8809f39164d,

title = "Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study",

abstract = "Introduction: Prior cross-sectional studies suggest that health-related quality of life (HRQOL) worsens with more severe glomerular disease. This longitudinal analysis was conducted to assess changes in HRQOL with changing disease status. Methods: Cure Glomerulonephropathy (CureGN) is a cohort of patients with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, IgA vasculitis, or IgA nephropathy. HRQOL was assessed at enrollment and follow-up visits 1 to 3 times annually for up to 5 years with the Patient-Reported Outcomes Measurement Information System (PROMIS). Global health, anxiety, and fatigue domains were measured in all; mobility was measured in children; and sleep-related impairment was measured in adults. Linear mixed effects models were used to evaluate HRQOL responsiveness to changes in disease status. Results: A total of 469 children and 1146 adults with PROMIS scores were included in the analysis. HRQOL improved over time in nearly all domains, though group-level changes were modest. Edema was most consistently associated with worse HRQOL across domains among children and adults. A greater number of symptoms also predicted worse HRQOL in all domains. Sex, age, obesity, and serum albumin were associated with some HRQOL domains. The estimated glomerular filtration rate (eGFR) was only associated with fatigue and adult physical health; proteinuria was not associated with any HRQOL domain in adjusted models. Conclusion: HRQOL measures were responsive to changes in disease activity, as indicated by edema. HRQOL over time was not predicted by laboratory-based markers of disease. Patient-reported edema and number of symptoms were the strongest predictors of HRQOL, highlighting the importance of the patient experience in glomerular disease. HRQOL outcomes inform understanding of the patient experience for children and adults with glomerular diseases.",

keywords = "edema, health-related quality of life, patient-reported outcomes, primary glomerular disease",

author = "{CureGN Consortium} and Murphy, {Shannon L.} and Mahan, {John D.} and Troost, {Jonathan P.} and Tarak Srivastava and Kogon, {Amy J.} and Yi Cai and Davis, {T. Keefe} and Hilda Fernandez and Alessia Fornoni and Gbadegesin, {Rasheed A.} and Emily Herreshoff and Canetta, {Pietro A.} and Nachman, {Patrick H.} and Reeve, {Bryce B.} and Selewski, {David T.} and Sethna, {Christine B.} and Wang, {Chia shi} and Bartosh, {Sharon M.} and Gipson, {Debbie S.} and Tuttle, {Katherine R.} and Ali Gharavi and Wooin Ahn and Appel, {Gerald B.} and Avasare, {Rupali S.} and Revekka Babayev and Ibrahim Batal and Bomback, {Andrew S.} and Eric Brown and Campenot, {Eric S.} and Pietro Canetta and Brenda Chan and D'Agati, {Vivette D.} and Bartosz Foroncewicz and Ghiggeri, {Gian Marco} and Hines, {William H.} and Jain, {Namrata G.} and Krzysztof Kiryluk and Fangming Lin and Francesca Lugani and Maddalena Marasa and Glen Markowitz and Sumit Mohan and Krzysztof Mucha and Nickolas, {Thomas L.} and Jai Radhakrishnan and Rao, {Maya K.} and Renu Regunathan-Shenk and Simone Sanna-Cherchi and Dominick Santoriello and Stokes, {Michael B.}",

note = "Funding Information: Funding for the CureGN consortium is provided by UM1DK100845, UM1DK100846, UM1DK100876, UM1DK100866, and UM1DK100867 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Patient recruitment is supported by NephCure Kidney International. This project was also supported in part by UL1TR002240 from the National Center for Advancing Translational Sciences (NCATS) for the Michigan Institute for Clinical and Health Research. Funding Information: JT owns equity/stock in General Electric and Procter & Gamble, and receives grant support from Pfizer Inc. TS receives consulting fees and advisory board membership fees from ALNYLAM and current grant support and research funding from National Institutes of Health–National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK), Bristol-Myers-Squibb, Retrophin, Mallinckdrodt, and Alexion; and royalty from UpToDate. HF reports current grant support RANSFORM KL2 Scholars Mentored Career Development “Genomic Disorders, Chronic Kidney Disease and Neurocognitive Status in Children.” AF receives consulting fees and advisory board membership fees from Variant Pharmaceutical, DImerix ONO; Equity/stock Variant Pharmaceutical (unrelated), NIH grant support. PHN reports current grant support from NIH Immune Tolerance Network. CBS receives consulting fees and advisory board membership fees from Kite Medical. CW reports lecture fees from Mallinckrodt Pharmaceuticals. SB reports current grant support for multicenter NIH-sponsored trials. DSG receives consulting fees and advisory board membership fees paid to the University of Michigan; current grant support from Retrophin, Complexa, BMS, Variant, Goldfinch, NIH; and additional support from Nephcure Kidney International is under negotiation. KRT receives consulting fees and advisory board membership fees from Eli Lilly and Company, Boehringer Ingelheim, Astra Zeneca, Gilead, Goldfinch Bio; lecture fees from Eli Lilly and Company, Astra Zeneca; travel support from Eli Lilly and Company; current grant support from NIDDK, NCATS, and CDC; and additional support from Goldfinch Bio is under negotiation. All the other authors declared no competing interests. Publisher Copyright: {\textcopyright} 2020",

year = "2020",

month = oct,

doi = "10.1016/j.ekir.2020.06.041",

language = "English (US)",

volume = "5",

pages = "1679--1689",

journal = "Kidney International Reports",

issn = "2468-0249",

publisher = "Elsevier Inc.",

number = "10",

}

TY - JOUR

T1 - Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease

T2 - Results From the CureGN Study

AU - CureGN Consortium

AU - Murphy, Shannon L.

AU - Mahan, John D.

AU - Troost, Jonathan P.

AU - Srivastava, Tarak

AU - Kogon, Amy J.

AU - Cai, Yi

AU - Davis, T. Keefe

AU - Fernandez, Hilda

AU - Fornoni, Alessia

AU - Gbadegesin, Rasheed A.

AU - Herreshoff, Emily

AU - Canetta, Pietro A.

AU - Nachman, Patrick H.

AU - Reeve, Bryce B.

AU - Selewski, David T.

AU - Sethna, Christine B.

AU - Wang, Chia shi

AU - Bartosh, Sharon M.

AU - Gipson, Debbie S.

AU - Tuttle, Katherine R.

AU - Gharavi, Ali

AU - Ahn, Wooin

AU - Appel, Gerald B.

AU - Avasare, Rupali S.

AU - Babayev, Revekka

AU - Batal, Ibrahim

AU - Bomback, Andrew S.

AU - Brown, Eric

AU - Campenot, Eric S.

AU - Canetta, Pietro

AU - Chan, Brenda

AU - D'Agati, Vivette D.

AU - Foroncewicz, Bartosz

AU - Ghiggeri, Gian Marco

AU - Hines, William H.

AU - Jain, Namrata G.

AU - Kiryluk, Krzysztof

AU - Lin, Fangming

AU - Lugani, Francesca

AU - Marasa, Maddalena

AU - Markowitz, Glen

AU - Mohan, Sumit

AU - Mucha, Krzysztof

AU - Nickolas, Thomas L.

AU - Radhakrishnan, Jai

AU - Rao, Maya K.

AU - Regunathan-Shenk, Renu

AU - Sanna-Cherchi, Simone

AU - Santoriello, Dominick

AU - Stokes, Michael B.

N1 - Funding Information: Funding for the CureGN consortium is provided by UM1DK100845, UM1DK100846, UM1DK100876, UM1DK100866, and UM1DK100867 from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). Patient recruitment is supported by NephCure Kidney International. This project was also supported in part by UL1TR002240 from the National Center for Advancing Translational Sciences (NCATS) for the Michigan Institute for Clinical and Health Research. Funding Information: JT owns equity/stock in General Electric and Procter & Gamble, and receives grant support from Pfizer Inc. TS receives consulting fees and advisory board membership fees from ALNYLAM and current grant support and research funding from National Institutes of Health–National Institute of Diabetes and Digestive and Kidney Diseases (NIH-NIDDK), Bristol-Myers-Squibb, Retrophin, Mallinckdrodt, and Alexion; and royalty from UpToDate. HF reports current grant support RANSFORM KL2 Scholars Mentored Career Development “Genomic Disorders, Chronic Kidney Disease and Neurocognitive Status in Children.” AF receives consulting fees and advisory board membership fees from Variant Pharmaceutical, DImerix ONO; Equity/stock Variant Pharmaceutical (unrelated), NIH grant support. PHN reports current grant support from NIH Immune Tolerance Network. CBS receives consulting fees and advisory board membership fees from Kite Medical. CW reports lecture fees from Mallinckrodt Pharmaceuticals. SB reports current grant support for multicenter NIH-sponsored trials. DSG receives consulting fees and advisory board membership fees paid to the University of Michigan; current grant support from Retrophin, Complexa, BMS, Variant, Goldfinch, NIH; and additional support from Nephcure Kidney International is under negotiation. KRT receives consulting fees and advisory board membership fees from Eli Lilly and Company, Boehringer Ingelheim, Astra Zeneca, Gilead, Goldfinch Bio; lecture fees from Eli Lilly and Company, Astra Zeneca; travel support from Eli Lilly and Company; current grant support from NIDDK, NCATS, and CDC; and additional support from Goldfinch Bio is under negotiation. All the other authors declared no competing interests. Publisher Copyright: © 2020

PY - 2020/10

Y1 - 2020/10

N2 - Introduction: Prior cross-sectional studies suggest that health-related quality of life (HRQOL) worsens with more severe glomerular disease. This longitudinal analysis was conducted to assess changes in HRQOL with changing disease status. Methods: Cure Glomerulonephropathy (CureGN) is a cohort of patients with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, IgA vasculitis, or IgA nephropathy. HRQOL was assessed at enrollment and follow-up visits 1 to 3 times annually for up to 5 years with the Patient-Reported Outcomes Measurement Information System (PROMIS). Global health, anxiety, and fatigue domains were measured in all; mobility was measured in children; and sleep-related impairment was measured in adults. Linear mixed effects models were used to evaluate HRQOL responsiveness to changes in disease status. Results: A total of 469 children and 1146 adults with PROMIS scores were included in the analysis. HRQOL improved over time in nearly all domains, though group-level changes were modest. Edema was most consistently associated with worse HRQOL across domains among children and adults. A greater number of symptoms also predicted worse HRQOL in all domains. Sex, age, obesity, and serum albumin were associated with some HRQOL domains. The estimated glomerular filtration rate (eGFR) was only associated with fatigue and adult physical health; proteinuria was not associated with any HRQOL domain in adjusted models. Conclusion: HRQOL measures were responsive to changes in disease activity, as indicated by edema. HRQOL over time was not predicted by laboratory-based markers of disease. Patient-reported edema and number of symptoms were the strongest predictors of HRQOL, highlighting the importance of the patient experience in glomerular disease. HRQOL outcomes inform understanding of the patient experience for children and adults with glomerular diseases.

AB - Introduction: Prior cross-sectional studies suggest that health-related quality of life (HRQOL) worsens with more severe glomerular disease. This longitudinal analysis was conducted to assess changes in HRQOL with changing disease status. Methods: Cure Glomerulonephropathy (CureGN) is a cohort of patients with minimal change disease, focal segmental glomerulosclerosis, membranous nephropathy, IgA vasculitis, or IgA nephropathy. HRQOL was assessed at enrollment and follow-up visits 1 to 3 times annually for up to 5 years with the Patient-Reported Outcomes Measurement Information System (PROMIS). Global health, anxiety, and fatigue domains were measured in all; mobility was measured in children; and sleep-related impairment was measured in adults. Linear mixed effects models were used to evaluate HRQOL responsiveness to changes in disease status. Results: A total of 469 children and 1146 adults with PROMIS scores were included in the analysis. HRQOL improved over time in nearly all domains, though group-level changes were modest. Edema was most consistently associated with worse HRQOL across domains among children and adults. A greater number of symptoms also predicted worse HRQOL in all domains. Sex, age, obesity, and serum albumin were associated with some HRQOL domains. The estimated glomerular filtration rate (eGFR) was only associated with fatigue and adult physical health; proteinuria was not associated with any HRQOL domain in adjusted models. Conclusion: HRQOL measures were responsive to changes in disease activity, as indicated by edema. HRQOL over time was not predicted by laboratory-based markers of disease. Patient-reported edema and number of symptoms were the strongest predictors of HRQOL, highlighting the importance of the patient experience in glomerular disease. HRQOL outcomes inform understanding of the patient experience for children and adults with glomerular diseases.

KW - edema

KW - health-related quality of life

KW - patient-reported outcomes

KW - primary glomerular disease

UR - http://www.scopus.com/inward/record.url?scp=85091686390&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85091686390&partnerID=8YFLogxK

U2 - 10.1016/j.ekir.2020.06.041

DO - 10.1016/j.ekir.2020.06.041

M3 - Article

C2 - 33102960

AN - SCOPUS:85091686390

SN - 2468-0249

VL - 5

SP - 1679

EP - 1689

JO - Kidney International Reports

JF - Kidney International Reports

IS - 10

ER -

Longitudinal Changes in Health-Related Quality of Life in Primary Glomerular Disease: Results From the CureGN Study

Abstract

Bibliographical note

Keywords

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this